Premium
High‐risk Molecules or Insufficient Scientific Data?
Author(s) -
Mignot A
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100460
Subject(s) - drug development , theme (computing) , engineering ethics , medicine , event (particle physics) , pharmacology , drug , risk analysis (engineering) , computer science , engineering , physics , quantum mechanics , operating system
When I was invited to author an ethics policy piece on the “approach to high‐risk molecules” as a contribution to the theme of “Innovation in Drug Development” of this Clinical Pharmacology & Therapeutics issue, I thought there was a need to evaluate whether questioning the transition from preclinical to clinical development after the TGN 1412 serious adverse event may freeze the development of innovating tools in drug development. Clinical Pharmacology & Therapeutics (2008); doi: 10.1038/sj.clpt.6100460